Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Lebwohl

Showing results (71-80 of 209) with videos related to

Pageof 21
Sort By:
Journal of the American Academy of Dermatology|August 19, 2015
Annual screening for tuberculosis in patients on TNF-alfa antagonistsSean D Doherty, Mark G Lebwohl, Abby S Van Voorhees, et al.
Journal of the American Academy of Dermatology|June 12, 2020
No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritisUlrich Mrowietz, Elisabeth Riedl, Stefan Winkler, et al.
Dermatology and Therapy|August 2, 2021
Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline CharacteristicsMark G Lebwohl, Kim A Papp, Marie Holst Mørch, et al.
Dermatology and Therapy|December 18, 2021
Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical TrialsMark G Lebwohl, Ahmed M Soliman, Hongbo Yang, et al.
Journal of Drugs in Dermatology : JDD|August 7, 2025
Resolving Hyperkeratotic Psoriasis: Mechanisms of Action and Additive Effects of Fixed-Combination Halobetasol Propionate and TazaroteneEmil A Tanghetti, Mark G Lebwohl, Linda Stein Gold, et al.
Journal of the American Academy of Dermatology|November 4, 2020
Risk of skin disorders in patients with celiac disease: A population-based cohort studyBenjamin Lebwohl, Jonas Söderling, Bjorn Roelstraete, et al.
The British Journal of Dermatology|January 4, 2022
Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and PARACELSUS criteria: a multicentre, retrospective cohort studyMichelle S Min, Kylee Kus, Nancy Wei, et al.
Archives of Dermatological Research|August 30, 2024
Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studiesEric L Simpson, Emma Guttman-Yassky, Jeffrey Pawlikowski, et al.
Journal of Drugs in Dermatology : JDD|September 28, 2010
A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratosesJoseph L Jorizzo, Orit Markowitz, Mark G Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|December 5, 2013
Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasisLeon Kircik, Mark G Lebwohl, James Q Del Rosso, et al.
Pageof 21

Showing results (71-80 of 209) with videos related to

Sort By:
Pageof 21
Journal of the American Academy of Dermatology|August 19, 2015
Annual screening for tuberculosis in patients on TNF-alfa antagonistsSean D Doherty, Mark G Lebwohl, Abby S Van Voorhees, et al.
Journal of the American Academy of Dermatology|June 12, 2020
No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritisUlrich Mrowietz, Elisabeth Riedl, Stefan Winkler, et al.
Dermatology and Therapy|August 2, 2021
Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline CharacteristicsMark G Lebwohl, Kim A Papp, Marie Holst Mørch, et al.
Dermatology and Therapy|December 18, 2021
Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical TrialsMark G Lebwohl, Ahmed M Soliman, Hongbo Yang, et al.
Journal of Drugs in Dermatology : JDD|August 7, 2025
Resolving Hyperkeratotic Psoriasis: Mechanisms of Action and Additive Effects of Fixed-Combination Halobetasol Propionate and TazaroteneEmil A Tanghetti, Mark G Lebwohl, Linda Stein Gold, et al.
Journal of the American Academy of Dermatology|November 4, 2020
Risk of skin disorders in patients with celiac disease: A population-based cohort studyBenjamin Lebwohl, Jonas Söderling, Bjorn Roelstraete, et al.
The British Journal of Dermatology|January 4, 2022
Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and PARACELSUS criteria: a multicentre, retrospective cohort studyMichelle S Min, Kylee Kus, Nancy Wei, et al.
Archives of Dermatological Research|August 30, 2024
Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studiesEric L Simpson, Emma Guttman-Yassky, Jeffrey Pawlikowski, et al.
Journal of Drugs in Dermatology : JDD|September 28, 2010
A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratosesJoseph L Jorizzo, Orit Markowitz, Mark G Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|December 5, 2013
Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasisLeon Kircik, Mark G Lebwohl, James Q Del Rosso, et al.
Pageof 21